Format

Send to

Choose Destination
Ther Adv Med Oncol. 2016 Jul;8(4):276-93. doi: 10.1177/1758834016646734. Epub 2016 May 29.

Current targeted therapies in the treatment of advanced colorectal cancer: a review.

Author information

1
St James's Hospital, Surgical Oncology, St James's St, Dublin 8, Ireland.
2
St James's Hospital, Dublin, Ireland.

Abstract

Treatment strategies for metastatic colorectal cancer (mCRC) patients have undergone dramatic changes in the past decade and despite improved patient outcomes, there still exist areas for continued development. The introduction of targeted agents has provided clinicians with additional treatment options in mCRC, however, results have been mixed at best. These novel therapies were designed to interfere with specific molecules involved in the cellular carcinogenesis pathway and ultimately deliver a more focused treatment. Currently, their use in mCRC has been limited primarily as an adjunct to conventional chemotherapy regimens. This review explores the relevant cell-signaling networks in colorectal cancer, provides focus on the current targeted agent armamentarium approved for use in mCRC and explores the usefulness of predictive mCRC biomarkers.

KEYWORDS:

biomarkers; colorectal cancer; signaling; targeted therapy

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center